✦ LIBER ✦

Phase I trial and pharmacokinetic (PK) study of S16020 according to a weekly and every 2 week (W) schedule in cancer patients (PT)

✍ Scribed by Brian, E.; Di Palma, M.; Etassami, A.; Quabdesselam, R.; Gérard, B.; Chouaki, N.; Lucas, C.; Brillanceau, M.H.; Giroux, B.; Turpin, F.; Misset, J.L.

Book ID: 122436300
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 269 KB
Volume: 35
Category: Article
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(99)81579-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

3040 POSTER Optimal dose for an every 2

3040 POSTER Optimal dose for an every 2 week (q2w) cetuximab (C) regimen in patients (pts) with metastatic colorectal cancer (mCRC): a phase I safety, pharmacokinetics (PK) and pharmacodynamics (PD) study of weekly (q1w) and q2w schedules

✍ F. Ciardiello; A. Cervantes; M. Vega-Villegas; E. Casado; E. Rodriguez-Braun; E. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 60 KB

550 Phase I and pharmacokinetic (PK) stu

550 Phase I and pharmacokinetic (PK) study of trabectedin (ET-743) administered as a 1-hour infusion weekly for 3 consecutive weeks every 4 weeks to patients with advanced cancer

✍ S.Q. Chu; G. Schwartz; M. Beeram; A. Patniak; M. Mita; J. Jimeno; L. Lopez-Laraz 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 273 KB

A phase I clinical and pharmacokinetic (

A phase I clinical and pharmacokinetic (PK) study with KahalalideF (KF) in patients (pts) with advanced solid tumors (AST) with a continuous weekly (W) 1-hour iv infusion schedule

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 139 KB

Phase I and pharmacokinetic study of lon

Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors

✍ Carlos Castaneda; Kellen L. Meadows; Roxanne Truax; Michael A. Morse; Scott H. K 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 358 KB

6058 Phase I/II study of weekly intermit

6058 Phase I/II study of weekly intermittent capecitabine with bevacizumab and oxaliplatin on an every-2-week schedule for patients with untreated advanced colorectal cancer (CRC) final results

✍ Ramanathan, R.K.; Sehgal, R.; Rajasenan, K.K.; Crandall, T.L.; Balaban, E.P.; Pi 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

A phase I pharmacokinetic (PK) and seria

A phase I pharmacokinetic (PK) and serial tumor and skin pharmacodynamic (PD) study of weekly, every 2 weeks or every 3 weeks 1-hour (h) infusion EMD72000, an humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (p) with advanced tumors known to overexpress the EGFR

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 256 KB